Caracterización molecular de carbapenemasas en el Perú durante el 2019

Maritza Miriam Mayta-Barrios; Juan José Ramirez-Illescas; Luis Pampa-Espinoza; Martin Javier Alfredo Yagui-Moscoso

doi:10.17843/rpmesp.2021.381.5882

Authors

Maritza Miriam Mayta-Barrios Laboratorio de Referencia Nacional de Infecciones Intrahospitalarias, Instituto Nacional de Salud, Lima, Perú.Bióloga, maestra en Ciencias https://orcid.org/0000-0002-9568-3400
Juan José Ramirez-Illescas Laboratorio de Referencia Nacional de Infecciones Intrahospitalarias, Instituto Nacional de Salud, Lima, Perú. biólogo https://orcid.org/0000-0002-3870-3129
Luis Pampa-Espinoza Unidad de Intervenciones Estratégicas, Instituto Nacional de Salud, Lima, Perú. médico infectólogo https://orcid.org/0000-0002-2392-587X
Martin Javier Alfredo Yagui-Moscoso Unidad de Intervenciones Estratégicas, Instituto Nacional de Salud, Lima, Perú. médico patólogo clínico https://orcid.org/0000-0002-3737-5709

DOI:

https://doi.org/10.17843/rpmesp.2021.381.5882

Keywords:

Drug resistance, Carbapenemases, Acinetobacter, Enterobacteriaceae, Pseudomonas, Peru

Abstract

Resistance to carbapenems is a public health problem. This study presents the identification of carbapenemase enzymes in Enterobacteriaceae, Pseudomonas spp. and Acinetobacter spp. present in strains from 30 institutions that provide health services in Peru as part of the quality control process in diagnoses.
Phenotypic confirmation and enzymatic identification were performed using the Blue CARBA test and the synergy test with phenylboronic acid and ethylenediaminetetraacetic acid/sodium mercaptoacetic acid discs. 185 strains with carbapenemases were identified: 78 in Enterobacteriaceae, 61 in P. aeruginosa and 46 in Acinetobacter spp. The types of carbapenemases identified were: blaKPC, blaNDM, blaIMP, blaVIM, blaOXA-23, blaOXA-24, blaOXA-51 and the blaVIM/IMP co-production. It is important to strengthen the promotion of the rational use of antimicrobials and epidemiological surveillance in the country's hospitals.